Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820456 | 1.00 | POLB (0.45) | POLBELANETSHRL3MBTL1TACR3 | |
| SCHEMBL375113 | 0.89 | ELANE (0.38) | POLBELANE | |
| SCHEMBL820670 | 0.85 | ELANE (0.36) | POLBELANE | |
| SCHEMBL820247 | 0.79 | MET (0.45) | POLBGRIN2B | |
| SCHEMBL820242 | 0.79 | MET (0.45) | POLBGRIN2B | |
| SCHEMBL374971 | 0.79 | MET (0.45) | POLBGRIN2B | |
| SCHEMBL10109808 | 0.79 | MET (0.45) | POLBGRIN2B | |
| SCHEMBL820466 | 0.75 | TSHR (0.45) | TSHRL3MBTL1GRIN2B | |
| SCHEMBL818648 | 0.75 | TSHR (0.45) | TSHRL3MBTL1GRIN2B | |
| SCHEMBL9812772 | 0.74 | POLB (0.50) | POLBTSHRL3MBTL1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049563-B1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARM CORP (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2409984-A1 | Dimeric IAP Antagonists | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-7985735-B2 | mimetics of the activity of the N-terminal portion of Smac/tertiary binding structure to IAPs, can be combined with chemotherapeutic agents like topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds; increased cell permeability, water solubility; antitumor agents | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | BIRC2, BIRC7, BIRC8 | POLB 3555/4885ELANE 2407/4885TSHR 4493/4885 |
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | POLB 3282/4885ELANE 616/4885TSHR 4584/4885 |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | BIRC2, BIRC7, BIRC8 | POLB 4023/4885ELANE 2140/4885TSHR 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.